Pharmacotherapy prescribing pattern and outcome for hospitalized patients with severe and critical COVID-19
Hayder Assad
Current Issues in Pharmacy and Medical Sciences, doi:10.2478/cipms-2022-0020
INTRODUCTION Coronavirus Disease 2019 (COVID-19) is a pandemic disease originating in late 2019 in the People's Republic of China that spread rapidly worldwide [1]. The first reported case in the Najaf governorate, Iraq, was confirmed on February 24, 2020 [2]. As of early June 2021, the global reported cases of COVID-19 have exceeded 170 million with over 3 million deaths [3]. The clinical spectrum of this illness ranges from asymptomatic infection, to acute respiratory distress syndrome (ARDS), circulatory shock, multiorgan failure, and ultimately death [4] . The death rate related to COVID-19 is relatively high -ranging from 5% to 35%, especially in elderly patients and those who have comorbidities [5] . Although different treatment strategies have been explored and used based on emergency approval and evidence-based
ORCID iDs Hayder Assad https://orcid.org/0000-0003-3499-3007
References
Alsharidah, Ayed, Ameen, Alhuraish, Rouheldeen et al., COVID-19 convalescent plasma treatment of moderate and severe cases of SARS-CoV-2 infection: A multicenter interventional study, Int J Infect Dis
Arshad, Kilgore, Chaudhry, Jacobsen, Wang et al., Treatment with hydroxychloroquine, azithromycin, and combination in patients hospitalized with COVID-19, Int J Infect Dis
Bajwah, Wilcock, Towers, Costantini, Bausewein et al., Managing the supportive care needs of those affected by COVID-19, Eur Respir J
Beigel, Tomashek, Dodd, Mehta, Zingman et al., Remdesivir for the treatment of COVID-19 -Final Report, N Engl J Med
Best, Kong, Kaplan-Lewis, Brawley, Baden et al., Treatment patterns in US patients hospitalized with COVID-19 and pulmonary involvement, J Med Virol
Campos Dm De, Fulco, De Oliveira, Oliveira, SARS-CoV-2 virus infection: Targets and antiviral pharmacological strategies, J Evid Based Med
Chappell, Horby, Lim, Emberson, Mafham et al., Dexamethasone in hospitalized patients with COVID-19 -preliminary report, N Engl J Med
Chibber, Haq, Ahmed, Andrabi, Singh, Advances in the possible treatment of COVID-19: A review, Eur J Pharmacol
Freedberg, Conigliaro, Wang, Tracey, Callahan et al., Famotidine use is associated with improved clinical outcomes in hospitalized COVID-19 patients: A propensity score matched retrospective cohort study, Gastroenterol
Kewan, Covut, Mj, Rose, Gopalakrishna et al., Tocilizumab for treatment of patients with severe COVID-19: A retrospective cohort study, E Clinical Medicine
Lin, Schneeweiss, Tesfaye, Andrea, Liu et al., Pharmacotherapy for hospitalized patients with COVID-19: Treatment patterns by disease severity, Drugs
Mk, Ma, Incidence of the COVID-19 in Iraq -Implications for travellers, Travel Med Infect Dis
Padhy, Mohanty, Das, Meher, Therapeutic potential of ivermectin as add on treatment in COVID 19: A systematic review and meta-analysis, J Pharm Pharm Sci
Phelan, Katz, Lo, The Novel Coronavirus Originating in Wuhan, China: Challenges for Global Health Governance, JAMA
Rattanaumpawan, Jirajariyavej, Lerdlamyong, Palavutitotai, Saiyarin, Real-world experience with favipiravir for treatment of COVID-19 in Thailand: Results from a multi-center observational study,
doi:10.1101/2020.06.24.20133249Richardson, Hirsch, Narasimhan, Crawford, Mcginn et al., Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City area, JAMA
Sahebnasagh, Avan, Saghafi, Mojtahedzadeh, Sadremomtaz et al., Pharmacological treatments of COVID-19, Pharmacol Rep
Salazar, Christensen, Graviss, Nguyen, Castillo et al., Treatment of Coronavirus Disease 2019 patients with convalescent plasma reveals a signal of significantly decreased mortality, Am J Pathol
Sanders, Monogue, Jodlowski, Cutrell, Pharmacologic treatments for Coronavirus Disease 2019 (COVID-19): A review, JAMA
Wang, Hu, Hu, Zhu, Liu et al., Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China, JAMA
Wang, Zhang, Du, Du, Zhao et al., Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebocontrolled, multicentre trial, Lancet
Watanabe, Kwon, Abeles, Jia, Mehta, Medication use patterns in hospitalized patients with COVID-19 in California During the pandemic, JAMA Netw Open
Who, None
Who, None
Zanasi, Mazzolini, Kantar, A reappraisal of the mucoactive activity and clinical efficacy of bromhexine, Multidiscip Respir Med
{ 'indexed': { 'date-parts': [[2022, 10, 23]],
'date-time': '2022-10-23T05:01:56Z',
'timestamp': 1666501316838},
'reference-count': 26,
'publisher': 'Walter de Gruyter GmbH',
'issue': '0',
'license': [ { 'start': { 'date-parts': [[2022, 10, 21]],
'date-time': '2022-10-21T00:00:00Z',
'timestamp': 1666310400000},
'content-version': 'unspecified',
'delay-in-days': 0,
'URL': 'http://creativecommons.org/licenses/by-nc-nd/3.0'}],
'content-domain': {'domain': [], 'crossmark-restriction': False},
'abstract': '<jats:title>Abstract</jats:title>\n'
' <jats:p>There are many treatment modalities for COVID-19 – with varied '
'outcome. Therefore, authors designed this study to assess prescribing patterns and the '
'clinical outcome for hospitalized patients with severe and critical COVID-19 so as to '
'determine the most effective approach.</jats:p>\n'
' <jats:p>Authors conducted a retrospective observational study on 346 adult '
'patients with either severe or critical COVID-19, who were admitted to public hospitals in '
'Al-Najaf city, Iraq from June to September 2020. Patients’ information, medications and '
'outcomes were collected from their medical records in the registered office of the '
'hospital.</jats:p>\n'
' <jats:p>A total of 346 patients were enrolled, with a majority of patients '
'being adults above 35 years old and male (70.2%). Most patients (81%) received corticosteroid '
'as dexamethasone, and about 45% of all patients were given convalescent plasma therapy, while '
'a few patients were prescribed antiviral favipiravir (23%) and lopinavir/ritonavir (19%). As '
'supportive care medications, anticoagulant such as enoxaparin was administered to most of the '
'patients (93%) and more than half of all patients received the broad-spectrum antibiotic, '
'meropenem.</jats:p>\n'
' <jats:p>The majority of the patients recovered and were discharged alive '
'(66%), however, the in- hospital mortality rate was 26%. Interestingly, patients treated with '
'enoxaparin alone or in combination with hydroxychloroquine were associated with better '
'outcome.</jats:p>\n'
' <jats:p>The prescribing pattern of COVID-19 specific medications and '
'supportive care is aligned with guideline recommendations and associated with a beneficial '
'therapeutic outcome.</jats:p>',
'DOI': '10.2478/cipms-2022-0020',
'type': 'journal-article',
'created': { 'date-parts': [[2022, 10, 21]],
'date-time': '2022-10-21T13:20:19Z',
'timestamp': 1666358419000},
'source': 'Crossref',
'is-referenced-by-count': 0,
'title': 'Pharmacotherapy prescribing pattern and outcome for hospitalized patients with severe and '
'critical COVID-19',
'prefix': '10.2478',
'volume': '0',
'author': [ { 'ORCID': 'http://orcid.org/0000-0003-3499-3007',
'authenticated-orcid': False,
'given': 'Hayder',
'family': 'Assad',
'sequence': 'first',
'affiliation': [ { 'name': 'Department of Clinical Pharmacy, Faculty of Pharmacy , '
'University of Kufa , Najaf , Iraq'}]}],
'member': '374',
'published-online': {'date-parts': [[2022, 10, 21]]},
'reference': [ { 'key': '2022102203230152355_j_cipms-2022-0020_ref_001',
'doi-asserted-by': 'crossref',
'unstructured': '1. Phelan AL, Katz R, Gostin LO. The Novel Coronavirus Originating in '
'Wuhan, China: Challenges for Global Health Governance. JAMA. '
'2020;323(8):709-10.10.1001/jama.2020.109731999307',
'DOI': '10.1001/jama.2020.1097'},
{ 'key': '2022102203230152355_j_cipms-2022-0020_ref_002',
'doi-asserted-by': 'crossref',
'unstructured': '2. Al-Malkey MK, Al-Sammak MA. Incidence of the COVID-19 in Iraq – '
'Implications for travellers. Travel Med Infect Dis. '
'2020;38:101739.10.1016/j.tmaid.2020.101739721936332405265',
'DOI': '10.1016/j.tmaid.2020.101739'},
{ 'key': '2022102203230152355_j_cipms-2022-0020_ref_003',
'unstructured': '3. WHO; 2021. [https://covid19.who.int/] (access: 04 June 2021)'},
{ 'key': '2022102203230152355_j_cipms-2022-0020_ref_004',
'doi-asserted-by': 'crossref',
'unstructured': '4. Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical '
'characteristics of 138 hospitalized patients with 2019 novel '
'coronavirus-infected pneumonia in Wuhan, China. JAMA. '
'2020;323(11):1061-9.10.1001/jama.2020.1585704288132031570',
'DOI': '10.1001/jama.2020.1585'},
{ 'key': '2022102203230152355_j_cipms-2022-0020_ref_005',
'doi-asserted-by': 'crossref',
'unstructured': '5. Richardson S, Hirsch JS, Narasimhan M, Crawford JM, McGinn T, '
'Davidson KW, et al. Presenting characteristics, comorbidities, and '
'outcomes among 5700 patients hospitalized with COVID-19 in the New York '
'City area. JAMA. '
'2020;323(20):2052-9.10.1001/jama.2020.6775717762932320003',
'DOI': '10.1001/jama.2020.6775'},
{ 'key': '2022102203230152355_j_cipms-2022-0020_ref_006',
'doi-asserted-by': 'crossref',
'unstructured': '6. Sanders JM, Monogue ML, Jodlowski TZ, Cutrell JB. Pharmacologic '
'treatments for Coronavirus Disease 2019 (COVID-19): A review. JAMA. '
'2020;323(18):1824-36.10.1001/jama.2020.601932282022',
'DOI': '10.1001/jama.2020.6019'},
{ 'key': '2022102203230152355_j_cipms-2022-0020_ref_007',
'doi-asserted-by': 'crossref',
'unstructured': '7. Bajwah S, Wilcock A, Towers R, Costantini M, Bausewein C, Simon ST, '
'et al. Managing the supportive care needs of those affected by COVID-19. '
'Eur Respir J. '
'2020;55(4):2000815.10.1183/13993003.00815-2020714426832269090',
'DOI': '10.1183/13993003.00815-2020'},
{ 'key': '2022102203230152355_j_cipms-2022-0020_ref_008',
'doi-asserted-by': 'crossref',
'unstructured': '8. Campos DM de O, Fulco UL, de Oliveira CBS, Oliveira JIN. SARSCoV-2 '
'virus infection: Targets and antiviral pharmacological strategies. J '
'Evid Based Med. 2020;13(4):255-60.10.1111/jebm.12414767531533058394',
'DOI': '10.1111/jebm.12414'},
{ 'key': '2022102203230152355_j_cipms-2022-0020_ref_009',
'doi-asserted-by': 'crossref',
'unstructured': '9. Sahebnasagh A, Avan R, Saghafi F, Mojtahedzadeh M, Sadremomtaz A, '
'Arasteh O, et al. Pharmacological treatments of COVID-19. Pharmacol Rep. '
'2020;72:1446-78.10.1007/s43440-020-00152-9743963932816200',
'DOI': '10.1007/s43440-020-00152-9'},
{ 'key': '2022102203230152355_j_cipms-2022-0020_ref_010',
'doi-asserted-by': 'crossref',
'unstructured': '10. Chappell L, Horby P, Lim WS, Emberson JR, Mafham M, Bell JL, et al. '
'Dexamethasone in hospitalized patients with COVID-19 – preliminary '
'report. N Engl J Med. '
'2021;384(8):693-704.10.1056/NEJMoa2021436738359532678530',
'DOI': '10.1056/NEJMoa2021436'},
{ 'key': '2022102203230152355_j_cipms-2022-0020_ref_011',
'doi-asserted-by': 'crossref',
'unstructured': '11. Kewan T, Covut F, Al-Jaghbeer MJ, Rose L, Gopalakrishna KV, Akbik B. '
'Tocilizumab for treatment of patients with severe COVID-19: A '
'retrospective cohort study. E Clinical Medicine. '
'2020;24:100418.10.1016/j.eclinm.2020.100418730550532766537',
'DOI': '10.1016/j.eclinm.2020.100418'},
{ 'key': '2022102203230152355_j_cipms-2022-0020_ref_012',
'unstructured': '12. WHO; 2021.[https://www.who.int/] (access: 28 June 2021)'},
{ 'key': '2022102203230152355_j_cipms-2022-0020_ref_013',
'doi-asserted-by': 'crossref',
'unstructured': '13. Best JH, Kong AM, Kaplan-Lewis E, Brawley OW, Baden R, Zazzali JL, '
'et al. Treatment patterns in US patients hospitalized with COVID-19 and '
'pulmonary involvement. J Med Virol. 2021;93:5367-75.10.1002/jmv.27049',
'DOI': '10.1002/jmv.27049'},
{ 'key': '2022102203230152355_j_cipms-2022-0020_ref_014',
'doi-asserted-by': 'crossref',
'unstructured': '14. Chibber P, Haq SA, Ahmed I, Andrabi NI, Singh G. Advances in the '
'possible treatment of COVID-19: A review. Eur J Pharmacol. '
'2020;883:173372.10.1016/j.ejphar.2020.173372',
'DOI': '10.1016/j.ejphar.2020.173372'},
{ 'key': '2022102203230152355_j_cipms-2022-0020_ref_015',
'doi-asserted-by': 'crossref',
'unstructured': '15. Lin KJ, Schneeweiss S, Tesfaye H, D’Andrea E, Liu J, Lii J, et al. '
'Pharmacotherapy for hospitalized patients with COVID-19: Treatment '
'patterns by disease severity. Drugs. '
'2020;80(18):1961-72.10.1007/s40265-020-01424-7',
'DOI': '10.1007/s40265-020-01424-7'},
{ 'key': '2022102203230152355_j_cipms-2022-0020_ref_016',
'unstructured': '16. Centers for Disease Control and Prevention. Guidance for COVID-19. '
'[https://www.cdc.gov/coronavirus/2019-ncov/communication/guidance.html] '
'(access: 27 June 0 2021).'},
{ 'key': '2022102203230152355_j_cipms-2022-0020_ref_017',
'doi-asserted-by': 'crossref',
'unstructured': '17. Watanabe JH, Kwon J, Nan B, Abeles SR, Jia S, Mehta SR. Medication '
'use patterns in hospitalized patients with COVID-19 in California During '
'the pandemic. JAMA Netw Open. '
'2021;4(5):e2110775.10.1001/jamanetworkopen.2021.10775',
'DOI': '10.1001/jamanetworkopen.2021.10775'},
{ 'key': '2022102203230152355_j_cipms-2022-0020_ref_018',
'doi-asserted-by': 'crossref',
'unstructured': '18. Beigel JH, Tomashek KM, Dodd LE, Mehta AK, Zingman BS, Kalil AC, et '
'al. Remdesivir for the treatment of COVID-19 – Final Report. N Engl J '
'Med. 2020;383(19):1813-26.10.1056/NEJMoa2007764',
'DOI': '10.1056/NEJMoa2007764'},
{ 'key': '2022102203230152355_j_cipms-2022-0020_ref_019',
'unstructured': '19. Wang Y, Zhang D, Du G, Du R, Zhao J, Jin Y, et al. Remdesivir in '
'adults with severe COVID-19: a randomised, double-blind, '
'placebo-controlled, multicentre trial. Lancet. '
'2020;395(10236):1569-78.10.1016/S0140-6736(20)31022-9'},
{ 'key': '2022102203230152355_j_cipms-2022-0020_ref_020',
'doi-asserted-by': 'crossref',
'unstructured': '20. Rattanaumpawan P, Jirajariyavej S, Lerdlamyong K, Palavutitotai N, '
'Saiyarin J. Real-world experience with favipiravir for treatment of '
'COVID-19 in Thailand: Results from a multi-center observational study. '
'MedRxiv. 2020. '
'[https://doi.org/10.1101/2020.06.24.20133249]10.1101/2020.06.24.20133249',
'DOI': '10.1101/2020.06.24.20133249'},
{ 'key': '2022102203230152355_j_cipms-2022-0020_ref_021',
'doi-asserted-by': 'crossref',
'unstructured': '21. Salazar E, Christensen PA, Graviss EA, Nguyen DT, Castillo B, Chen '
'J, et al. Treatment of Coronavirus Disease 2019 patients with '
'convalescent plasma reveals a signal of significantly decreased '
'mortality. Am J Pathol. '
'2020;190(11):2290-303.10.1016/j.ajpath.2020.08.001741790132795424',
'DOI': '10.1016/j.ajpath.2020.08.001'},
{ 'key': '2022102203230152355_j_cipms-2022-0020_ref_022',
'doi-asserted-by': 'crossref',
'unstructured': '22. Alsharidah S, Ayed M, Ameen RM, Alhuraish F, Rouheldeen NA, '
'Alshammari FR, et al. COVID-19 convalescent plasma treatment of moderate '
'and severe cases of SARS-CoV-2 infection: A multicenter interventional '
'study. Int J Infect Dis. '
'2021;103:439-46.10.1016/j.ijid.2020.11.198771777233285283',
'DOI': '10.1016/j.ijid.2020.11.198'},
{ 'key': '2022102203230152355_j_cipms-2022-0020_ref_023',
'doi-asserted-by': 'crossref',
'unstructured': '23. Arshad S, Kilgore P, Chaudhry ZS, Jacobsen G, Wang DD, Huitsing K, '
'et al. Treatment with hydroxychloroquine, azithromycin, and combination '
'in patients hospitalized with COVID-19. Int J Infect Dis. '
'2020;97:396-403.10.1016/j.ijid.2020.06.099733057432623082',
'DOI': '10.1016/j.ijid.2020.06.099'},
{ 'key': '2022102203230152355_j_cipms-2022-0020_ref_024',
'doi-asserted-by': 'crossref',
'unstructured': '24. Freedberg DE, Conigliaro J, Wang TC, Tracey KJ, Callahan MV, Abrams '
'JA, et al. Famotidine use is associated with improved clinical outcomes '
'in hospitalized COVID-19 patients: A propensity score matched '
'retrospective cohort study. Gastroenterol. '
'2020;159(3):1129-31.e3.10.1053/j.gastro.2020.05.053724219132446698',
'DOI': '10.1053/j.gastro.2020.05.053'},
{ 'key': '2022102203230152355_j_cipms-2022-0020_ref_025',
'doi-asserted-by': 'crossref',
'unstructured': '25. Padhy BM, Mohanty RR, Das S, Meher BR. Therapeutic potential of '
'ivermectin as add on treatment in COVID 19: A systematic review and '
'meta-analysis. J Pharm Pharm Sci. '
'2020;23:462-9.10.18433/jpps3145733227231',
'DOI': '10.18433/jpps31457'},
{ 'key': '2022102203230152355_j_cipms-2022-0020_ref_026',
'doi-asserted-by': 'crossref',
'unstructured': '26. Zanasi A, Mazzolini M, Kantar A. A reappraisal of the mucoactive '
'activity and clinical efficacy of bromhexine. Multidiscip Respir Med. '
'2017;12(1):1-14.10.1186/s40248-017-0088-1535981728331610',
'DOI': '10.1186/s40248-017-0088-1'}],
'container-title': 'Current Issues in Pharmacy and Medical Sciences',
'original-title': [],
'language': 'en',
'link': [ { 'URL': 'https://www.sciendo.com/pdf/10.2478/cipms-2022-0020',
'content-type': 'unspecified',
'content-version': 'vor',
'intended-application': 'similarity-checking'}],
'deposited': { 'date-parts': [[2022, 10, 22]],
'date-time': '2022-10-22T03:23:54Z',
'timestamp': 1666409034000},
'score': 1,
'resource': {'primary': {'URL': 'https://www.sciendo.com/article/10.2478/cipms-2022-0020'}},
'subtitle': [],
'short-title': [],
'issued': {'date-parts': [[2022, 10, 21]]},
'references-count': 26,
'journal-issue': {'issue': '0', 'published-online': {'date-parts': [[2022, 10, 21]]}},
'alternative-id': ['10.2478/cipms-2022-0020'],
'URL': 'http://dx.doi.org/10.2478/cipms-2022-0020',
'relation': {},
'ISSN': ['2300-6676'],
'subject': ['Pharmacology', 'Molecular Biology', 'General Medicine', 'Biochemistry'],
'published': {'date-parts': [[2022, 10, 21]]}}
